Cancer Research Horizons

Cancer Research UK and NovalGen have signed an agreement to bring NovalGen’s next-generation T-cell engager, NVG-222, into a first-in-human clinical trial.

Cancer Research Horizons, the innovation arm of Cancer Research UK, is partnering with Diamond Light Source, the UK’s national synchrotron, to build a world-leading fragment-based drug discovery programme.

Cancer Research Horizons, the innovation arm of Cancer Research UK, has appointed Carlos Garcia-Echeverria, Katharina Kreymborg and Karen Lackey as the first members of its Therapeutic Innovation board to steer its drug discovery strategy.

Suil Vision, the first start-up to emerge from the Cancer Grand Challenges programme, has launched with £500k of seed funding from Cancer Research Horizons. The new company aims to create a market-ready biological data visualisation tool for researchers.

With an initial investment of £28 million in resource and funding from LifeArc and Cancer Research UK, the consortium will bring together researchers, clinicians, scientists and industry to provide support, finance and expertise to progress innovations for children and young people’s cancers.

Tessellate BIO today announces the appointment of Dr. Lara Boyd as Chief Business Officer.